CRISPR-edited isogenic cell models offer a more relevant option for studying disease progression and therapeutic efficacy. By targeting specific genes and generating disease-causing mutations, it's possible to better recapitulate human disease in a dish. Learn more about ATCC's CRISPR-edited isogenic cell models.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?